Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients

Valeska Hofmeister-Mueller, Claudia S Vetter-Kauczok, Ramona Ullrich, Katharina Meder, Eugene Lukanidin, Eva-Bettina Broecker, Per thor Straten, Mads Hald Andersen, David Schrama, Juergen C Becker

Abstract

S100A4 (metastasin 1) belongs to the S100 family of Ca(2+) binding proteins. While not present in most differentiated adult tissues, S100A4 is upregulated in the micromilieu of tumors. It is primarily expressed by tumor-associated macrophages, fibroblasts, and tumor endothelial cells. Due to its strong induction in tumors S100A4 is a promising target for cancer immunotherapy. By reverse immunology, using epitope prediction programs, we identified 3 HLA-A1-restricted peptide epitopes (S100A4 A1-1, A1-2, and A1-3) which are subject to human T cell responses as detected in peripheral blood of melanoma patients by means of IFN-gamma ELISPOT and cytotoxicity assays. In addition, IFN-gamma responses to S100A4 A1-2 can not only be induced by stimulation of T cells with peptide-loaded DC but also by stimulation with S100A4 protein-loaded DC, indicating that this epitope is indeed generated by processing of the endogenously expressed protein. In addition, S100A4 A1-2 reactive T cells demonstrate lysis of HLA-A1(+) fibroblasts in comparison to HLA-A1(-) fibroblasts. In summary, this HLA-A1-restricted peptide epitope is a candidate for immunotherapeutical approaches targeting S100A4-expressing cells in the tumor stroma.

OriginalsprogEngelsk
TidsskriftCancer Immunology and Immunotherapy
Vol/bind58
Udgave nummer8
Sider (fra-til)1265-73
Antal sider9
ISSN0340-7004
DOI
StatusUdgivet - aug. 2009

Fingeraftryk

Dyk ned i forskningsemnerne om 'Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients'. Sammen danner de et unikt fingeraftryk.

Citationsformater